



THE UNIVERSITY OF CHICAGO

# ANNUAL UPDATES FROM ASH 2022

## ACCREDITATION AND CREDIT DESIGNATION STATEMENT

**PHYSICIAN CREDIT:** The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 7.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**NURSING CREDIT:** University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn 7.25 contact hours.

**AMERICAN BOARD OF INTERNAL MEDICINE MOC II CREDIT:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity providers responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**AMERICAN BOARD OF PEDIATRICS MOC PART II CREDIT:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

**OTHER HEALTH PROFESSIONAL CREDIT:** Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.



AT THE FOREFRONT

## UChicago Medicine

The University of Chicago  
Center for Continuing  
Medical Education  
5841 S. Maryland Ave., MC 1137  
Chicago, IL 60637


Follow us on Twitter: @UChicagoCME



### FOR MORE INFORMATION AND TO REGISTER:

Scan the QR code or visit [www.ChicagoPostASH.com](http://www.ChicagoPostASH.com)

**QUESTIONS?** Contact Meeting Achievements at  
[Janelle@meetingachievements.com](mailto:Janelle@meetingachievements.com) Or 219.465.1115



THE UNIVERSITY OF CHICAGO

# ANNUAL UPDATES FROM ASH 2022

## PRACTICE CHANGING ABSTRACTS

# FRIDAY, FEBRUARY 24, 2023

## HYBRID FORMAT: VIRTUAL + LIMITED IN-PERSON ATTENDANCE



AT THE FOREFRONT

## UChicago Medicine

### COURSE DIRECTOR

Michael Bishop, MD | Professor of Medicine  
Director of the Jonas Center for Cellular Therapy  
University of Chicago Medicine

## [www.ChicagoPostASH.com](http://www.ChicagoPostASH.com)

CONTINUING EDUCATION ACCREDITATION BY UNIVERSITY OF CHICAGO

## PROGRAM INFORMATION

### COURSE DESCRIPTION

This activity's goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, this activity will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths, including CAR T-cell therapy and novel therapeutics for the state-of-the-art management of newly-diagnosed and relapsed blood cancers. It will keep all healthcare professionals who care for patients with hematologic malignancies abreast of the latest scientific updates, innovative ideas, and the timeliest issues related to their care.

It will also provide participants with information to improve patient management and care strategies. They will discuss rapidly evolving developments, discover new treatments for patients, and improve practice paradigms. This activity will educate them on best practices for treating hematologic cancers and inform them of the indications to refer patients for expert quaternary-level care for advanced cellular therapies.

### TARGET AUDIENCE

This activity is designed for primary care physicians, hematologists, pathologists, medical oncologists, resident and fellow trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to the treatment of hematologic cancers.

### LEARNING OBJECTIVES

After this activity, participants will be able to:

1. Illustrate how cutting-edge data presented at the 2022 Annual Meeting of the American Society of Hematology can apply to clinical practice;
2. State the emerging treatment strategies for patients with low-risk and high-risk myeloid malignancies;
3. Discuss the optimal patient selection, timing, and regimen for transplant;
4. Evaluate clinical trial data in the context of CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards;
5. Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines;
6. Identify methods for integrating therapeutic advances into practice to improve current myeloma patient care;
7. Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common benign hematologic diseases and COVID-associated hematologic diseases.

### CONFERENCE LOCATION

#### IN-PERSON:

Convene | 333 N Green Street | Chicago, IL 60607

#### VIRTUAL:

Log in information will be sent 72 hours prior to conference.

## AGENDA

### PRE-CONFERENCE

8:15 am **REGISTRATION/  
BREAKFAST**

8:45 am **Fellows Meet the Expert**  
Speaker Laurie H. Sehn, MD, MPH  
University of British Columbia

9:30 am **CONCURRENT SESSIONS**

**Fellows: Case Based  
Clinical Trial Considerations**  
Speaker Jennifer Cooperrider, MD  
University of Chicago

**Allied Health/  
Nursing Session**  
Speaker Mylove Mortel, MSPH, RN  
University of Chicago

10:30 am **BREAK | VISIT EXHIBITS |  
NETWORKING**

### MAIN CONFERENCE

11:00 am **KEYNOTE: New Treatment  
Strategies in Lymphoma**  
Speaker Laurie H. Sehn, MD, MPH  
University of British Columbia

12:00 pm **LUNCH | VISIT EXHIBITS |  
NETWORKING**

12:30 pm **PANEL TOPICS:  
Immunotherapies and  
Non-cell Therapy  
Strategies in MM, ALL,  
Immunotherapy and CAR-T  
in Myeloid Malignancies**  
Moderator Sonali Smith, MD  
University of Chicago  
Panelists Andrzej Jakubowiak, MD, PhD  
Adam DuVall, MD, MPH  
Hongtao Liu, MD, PhD  
University of Chicago

1:00 pm **Cell Therapy in Multiple  
Myeloma**  
Speaker Benjamin Derman, MD  
University of Chicago

1:30 pm **MCL & CAR-T**  
Speaker Peter Riedell, MD  
University of Chicago

2:00 pm **BREAK | VISIT EXHIBITS |  
NETWORKING**

2:15 pm **Non-Malignant  
Hematology**  
Speaker Kenneth Cohen, MD  
University of Chicago

2:45 pm **Leukemia, Cell Therapy,  
and Older Adults**  
Speaker Mariam Nawas, MD  
University of Chicago

3:15 pm **BREAK | VISIT EXHIBITS |  
NETWORKING**

3:30 pm **Myelofibrosis Overview  
and Treatment Strategies**  
Speaker Satya Kosuri, MD  
University of Chicago

4:00 pm **Lymphoma & CLL:  
Immuno-, Non-  
Immunotherapies Plus  
Cell Therapy**  
Speaker Justin Kline, MD  
University of Chicago

4:30 pm **AML/MDS**  
Speaker Toyosi Odenike, MD  
University of Chicago

5:00 pm **MPN**  
Speaker Anand Patel, MD  
University of Chicago

5:30 pm **ADJOURN**

*Michael Bishop, MD will be the Moderator  
unless indicated otherwise*

## FACULTY

### COURSE DIRECTOR



**Michael Bishop, MD**  
Professor of Medicine  
Director of the Jonas Center  
for Cellular Therapy  
University of Chicago Medicine

### KEYNOTE SPEAKER



**Laurie H. Sehn, MD, MPH**  
Chair, Lymphoma  
Tumour Group  
BC Cancer Centre for  
Lymphoid Cancer  
Clinical Professor of Medicine  
Division of Medical Oncology  
University of British Columbia  
Associate Editor, Blood



**FOR MORE  
INFORMATION  
AND TO REGISTER  
SCAN THE QR CODE  
OR GO TO:**

### UNIVERSITY OF CHICAGO FACULTY

**Kenneth Cohen, MD**  
Associate Professor of Medicine

**Benjamin A. Derman, MD**  
Assistant Professor of Medicine

**Adam DuVall, MD, MPH**  
Assistant Professor of Medicine

**Andrzej Jakubowiak, MD, PhD**  
Professor of Medicine,  
Director, Myeloma Program

**Justin Kline, MD**  
Associate Professor of Medicine,  
Director, Lymphoma Program

**Satyajit Kosuri, MD**  
Assistant Professor of Medicine

**Hongtao Liu, MD, PhD**  
Associate Professor of Medicine

**Mariam Nawas, MD**  
Assistant Professor of Medicine

**Toyosi Odenike, MD**  
Professor of Medicine,  
Director, Leukemia Program

**Anand Patel, MD**  
Assistant Professor of Medicine

**Peter A. Riedell, MD**  
Assistant Professor of Medicine

**Sonali Smith, MD**  
Elwood V. Jensen Professor in Medicine,  
Chief, Section of Hematology/Oncology

**REGISTER TODAY:** [www.ChicagoPostASH.com](http://www.ChicagoPostASH.com)